Clinical trials: ALS (Amyotrophic Lateral Sclerosis)
Spinal Cord Injuries, Multiple Sclerosis
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT04721717
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis
The goal of this observational study is to understand the clinical variability in a population of ALS patients using multidimensional biomarkers.
- Trial name
- DRIVEALS (NCT06318598)
- Where
- 3 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis, ALS
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support.
- Trial name
- NCT03324399
- Testing
- probiotic
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avera McKennan Hospital & University Health Center
ALS
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period.
- Trial name
- NCT05568615
- Testing
- MT-1186
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral…
- Trial name
- NCT01906658
- Testing
- Repository corticotropin injection
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mallinckrodt
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), or asymptomatic carriers…
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NADALS (NCT05189106)
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
ALS - Amyotrophic Lateral Sclerosis
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded…
- Trial name
- CALM (NCT06649955)
- Testing
- Multi-site direct current stimulation (DCS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- PathMaker Neurosystems Inc.
Amyotrophic Lateral Sclerosis, ALS
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS.
- Trial name
- NCT04259255
- Testing
- Edaravone (Radicava®/Radicava ORS®)
- Where
- 20 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
ALS Study Determining Various Biomarkers and Strength Comparison After Exercise
The purpose of this study is to determine the muscle strength of a muscle in the thigh after 12 weeks of home exercise.
- Trial name
- ADVANCE (NCT03201991)
- Testing
- Resistance Exercise Program
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis (ALS)
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy
- Trial name
- ALS (NCT03580616)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Elijah W. Stommel
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function.
- Trial name
- ReALiSe (NCT06441682)
- Testing
- ARGX-119
- Where
- 9 sites in Belgium, Canada and 4 more
- Volunteers
- 60 people
- Sponsor
- argenx
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Amyotrophic Lateral Sclerosis
Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis
The investigators' preliminary studies demonstrated that repetitive transcranial magnetic stimulation (rTMS) of the brain may determine a slight slowing in the rate of disease progression in ALS patients (Di Lazzaro et al 2004…
- Trial name
- rTMS-ALS (NCT00833820)
- Testing
- Real rTMS of the brain
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Catholic University of the Sacred Heart